Is Astellas Pharma Inc. (ALPMY) a Buy, Sell, or Hold?
OTC : ALPMY
Astellas Pharma Inc. — News
$14.79 USD
$0.5 (3.5%)
- Volume
- 2.9K
- Average Volume
- 202.79K
- Market Capitalization
- $26.52B
- P/E Ratio
- 11.42
- Dividend Yield
- 3.35%
- Price Target
- Year High
- $17.35
- Year Low
- $10.03
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.38
- Current Ratio
- $1.20
| Source | Headline |
|---|---|
|
New Strong Sell Stocks for August 6th
COIN, ALPMY and MUX have been added to the Zacks Rank #5 (Strong Sell) List on August 6th, 2026. zacks.com - 2026-08-06 05:31:05 |
|
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Here is how Astellas Pharma Inc. (ALPMY) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year. zacks.com - 2026-06-22 10:41:24 |
|
Is Astellas Pharma (ALPMY) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 2026-06-22 10:41:23 |
|
Is Astellas Pharma (ALPMY) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 2026-06-05 10:40:44 |
|
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
Here is how Astellas Pharma Inc. (ALPMY) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year. zacks.com - 2026-06-05 10:40:43 |
|
Astellas Pharma Inc. (ALPMY) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Astellas Pharma Inc. (ALPMY) Presents at Jefferies Global Healthcare Conference 2026 Transcript seekingalpha.com - 2026-06-04 12:51:54 |
|
Astellas Targets ¥4.3 Trillion Profit Push As Xtandi Pressure Builds
Astellas Pharma (ALPMY) is trying to give investors a new growth story as Xtandi, its blockbuster prostate cancer drug co-marketed with Pfizer (PFE), moves clos gurufocus.com - 2026-05-26 13:18:00 |
|
MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer
Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand treatment options. zacks.com - 2026-05-25 13:26:05 |
|
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Here is how Astellas Pharma Inc. (ALPMY) and BillionToOne (BLLN) have performed compared to their sector so far this year. zacks.com - 2026-05-13 10:40:33 |
